Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$1.12
-0.9%		$1.56
$0.84
▼
$2.68
$5.41M0.27117,922 shs1,634 shs
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$2.40
+1.0%		$2.44
$1.70
▼
$14.85
N/AN/A115,290 shs6,533 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$3.40
+7.9%		$5.53
$3.05
▼
$70.60
N/AN/A233,790 shs12,236 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$3.80
+1.3%		$5.87
$8.50
▼
$23.00
$23.76MN/A37,647 shs16,652 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-0.88%-13.08%-38.25%-15.67%-53.88%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-2.86%-6.30%+25.26%+3.03%-83.18%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+1.61%-3.37%-40.23%-58.64%-92.28%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-6.25%-6.25%-39.95%-14.77%-68.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$1.12
-0.9%		$1.56
$0.84
▼
$2.68
$5.41M0.27117,922 shs1,634 shs
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$2.40
+1.0%		$2.44
$1.70
▼
$14.85
N/AN/A115,290 shs6,533 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$3.40
+7.9%		$5.53
$3.05
▼
$70.60
N/AN/A233,790 shs12,236 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$3.80
+1.3%		$5.87
$8.50
▼
$23.00
$23.76MN/A37,647 shs16,652 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-0.88%-13.08%-38.25%-15.67%-53.88%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-2.86%-6.30%+25.26%+3.03%-83.18%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+1.61%-3.37%-40.23%-58.64%-92.28%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
-6.25%-6.25%-39.95%-14.77%-68.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
2.00
Hold$28.002,400.00% Upside
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
2.50
Moderate Buy$20.33745.81% Upside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.40
Hold$110.003,135.29% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALZN, IZTC, IMMP, and ATOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/14/2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
9/8/2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
8/31/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
8/17/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (E+) ➝ Sell (E)
8/3/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/AN/A
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/A-$2.30N/AN/AN/AN/AN/AN/A12/8/2026 (Estimated)
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A-$3.11N/AN/AN/AN/AN/AN/A11/11/2026 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest ALZN, IZTC, IMMP, and ATOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$0.86N/AN/AN/AN/AN/A
9/10/2026Q1 2027
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$0.56-$0.68-$0.12-$0.68N/AN/A
8/7/2026Q2 2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$1.02-$0.95+$0.07-$0.95N/AN/A
7/30/2026Q4 2026
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A-$1.80N/A-$0.0850N/A$3.68 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/A
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
49.61%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
1.39%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
9.80%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
64.83 million4.76 millionNo Data
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
14N/A9.00 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
53N/A7.15 millionOptionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

Recent News About These Companies

Invizyne Technologies (NASDAQ:IZTC) Shares Down 4.9% - Time to Sell?
October 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31152025
Institutional investors own a significant stake of 42% in Invizyne Technologies, Inc. (NASDAQ:IZTC)
February 13, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/institutional-investors-own-significant-stake-122811776.html
What’s in a Name: Out with Invizyne, In with eXoZymes
February 12, 2025  |  genengnews.comG
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-rebrands-as-exozymes-with-new-ticker-exoz/ar-AA1yLfmv
Invizyne announces corporate name change to eXoZymes
February 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-announces-corporate-name-change-to-exozymes-1034336391
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 12.35%
February 4, 2025  |  aaii.comA
Why Invizyne Technologies, Inc.’s (IZTC) Stock Is Up 10.33%
January 30, 2025  |  aaii.comA
Invizyne technologies CEO Michael Heltzen buys $20,345 in stock
January 21, 2025  |  msn.comhttps://www.msn.com/en-us/technology/tech-companies/invizyne-technologies-ceo-michael-heltzen-buys-20-345-in-stock/ar-AA1xAdEg
Invizyne Technologies Inc trading resumes
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-resumes-1034183742
Invizyne Technologies Inc trading halted, volatility trading pause
January 1, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/invizyne-technologies-inc-trading-halted-volatility-trading-pause-1034183743
Michael Heltzen Buys 1,984 Shares of Invizyne Technologies Inc. (NASDAQ:IZTC) Stock
November 20, 2024  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-iztc-insider-buying-and-selling-2024-11-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alzamend Neuro stock logo

Alzamend Neuro NASDAQ:ALZN

$1.12 -0.01 (-0.88%)
As of 11:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$2.40 +0.02 (+1.01%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$3.40 +0.25 (+7.94%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$3.80 +0.05 (+1.33%)
As of 10/27/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas